NLRP3 and neoplasm: Additional discussion is provided regarding the influence that the genetics of this inflammasome pathway may have on immunotherapy resistance and in the identification of those tumors more likely to be responsive to the pharmacologic inhibition of the tumor NLRP3-HSP70 signaling axis.